Trial Profile
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2011
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms Nordic-VI
- 25 Jun 2011 Quality of life results presented at the 13th World Congress on Gastrointestinal Cancer.
- 05 Nov 2010 New trial record.